Altimmune (NASDAQ:ALT) Releases Earnings Results, Misses Expectations By $0.01 EPS

Altimmune (NASDAQ:ALT) posted its quarterly earnings results on Thursday. The company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.01), Zacks reports. Altimmune had a negative net margin of 22,645.37% and a negative return on equity of 46.96%. The company had revenue of $0.01 million for the quarter. During the same period last year, the firm posted ($0.32) EPS.

Altimmune Stock Down 2.5 %

Altimmune stock traded down $0.16 during mid-day trading on Friday, hitting $6.17. The company’s stock had a trading volume of 2,545,232 shares, compared to its average volume of 4,437,680. The stock has a market capitalization of $437.47 million, a P/E ratio of -3.88 and a beta of 0.13. Altimmune has a twelve month low of $2.09 and a twelve month high of $14.84. The stock’s fifty day moving average price is $6.63 and its two-hundred day moving average price is $8.07.

Analyst Ratings Changes

Several analysts have commented on the stock. B. Riley reaffirmed a “buy” rating and issued a $20.00 target price on shares of Altimmune in a research note on Tuesday, June 25th. JMP Securities lowered their target price on shares of Altimmune from $25.00 to $24.00 and set a “market outperform” rating for the company in a research note on Friday, May 10th. Piper Sandler reissued an “overweight” rating and set a $25.00 price objective on shares of Altimmune in a research note on Friday, June 21st. Guggenheim cut shares of Altimmune from a “buy” rating to a “neutral” rating in a research note on Monday, April 29th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $12.00 price target on shares of Altimmune in a research report on Tuesday, May 14th. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $18.80.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.